ISSUE 1314
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Milnacipran (Savella – Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a gamma-aminobutyric acid (GABA) analog similar to gabapentin also approved for treatment of diabetic neuropathy, post-herpetic neuralgia and epilepsy,1 and duloxetine, an SNRI also approved for treatment of depression, diabetic neuropathy and generalized anxiety disorder.2
FIBROMYALGIA — Fibromyalgia is characterized by chronic musculoskeletal pain, tenderness, fatigue and sleep disturbance. Genetic, environmental and psychosocial factors appear to influence its expression.3-5
In addition to the FDA-approved drugs, medications used to treat fibromyalgia have included analgesics, muscle relaxants, anticonvulsants, and antidepressants
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1314b
Electronic, downloadable article - $45